Zydus Lifesciences Ltd.
Price
Daily candles · NSEPrice history isn’t available for this scrip.
What the numbers say
- Good return on equity: 3-year ROE 20.4%.
- Comfortable leverage: debt-to-equity of 0.43.
- Sales compounded at 16.4% over 3 years.
- Weak cash conversion (CFO/OP 0.55).
- Trades below its industry P/E (22.6 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Zydus Lifesciences’ arm partners with Prolific Machines
Zylidac will first complete a tech transfer of Prolific's process at 50- liter scale to reproduce Prolific's results at the Zylidac site
- Zydus Lifesciences gets USFDA’s final nod for Estradiol and Levonorgestrel Transdermal System
Estradiol and Levonorgestrel Transdermal System is primarily used treat moderate to severe symptoms of menopause
- Zydus Lifesciences’ JV to set up pharmaceutical manufacturing facility in Sri Lanka
Zydus Sunshine Lifesciences has inked an agreement with the Board of Investment of Sri Lanka
- USFDA concludes inspection of Zydus Lifesciences’ Ahmedabad plant with 5 observations
The inspection was conducted from October 5, 2026 to October 13, 2026
- Zydus Lifesciences launches Riociguat Tablets in US in partnership with MSN Laboratories
The product was developed and is manufactured by MSN
- Zydus Lifesciences receives one observation from USFDA for Ahmedabad plant
The USFDA conducted cGMP inspection at the said facility from September 21 to 28, 2026
- USFDA concludes onsite inspection at Zydus Lifesciences’ New Jersey office
The inspection closed with NIL observations
- Zydus Lifesciences incorporates wholly owned subsidiary
The company has incorporated WOS in the name of 'Zydus Global Treasury Centre IFSC'
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 27,148 | 23,242 | 19,547 | 17,237 | 15,110 |
| Other income | 1,795 | 460 | 369 | 475 | 391 |
| Total Income | 28,943 | 23,701 | 19,917 | 17,712 | 15,501 |
| Expenditure | 19,958 | 16,348 | 14,248 | 13,666 | 11,935 |
| Operating Profit | 8,985 | 7,353 | 5,668 | 4,047 | 3,565 |
| Interest | 439 | 191 | 81 | 130 | 127 |
| Depreciation | 1,408 | 916 | 764 | 723 | 713 |
| Profit before tax | 6,621 | 6,027 | 4,809 | 2,590 | 2,838 |
| Tax | 1,595 | 1,412 | 978 | 588 | 512 |
| Net Profit | 5,026 | 4,615 | 3,831 | 2,002 | 2,326 |
| EPS (₹) | 50.09 | 44.97 | 38.14 | 19.30 | — |
| Net margin % | 18.5 | 19.9 | 19.6 | 11.6 | 15.4 |
Consolidated figures, as filed with the exchanges. Newest year first. EPS for FY22 is not shown: the value supplied does not agree with the number of shares the company reported for that year, and we would rather show nothing than a figure we cannot reconcile.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 101 | 101 | 101 | 101 | 102 |
| Reserves | 27,011 | 23,853 | 19,729 | 17,415 | 16,897 |
| Net worth | 27,111 | 23,953 | 19,830 | 17,516 | 17,000 |
| Total sources | 34,961 | 27,648 | 23,495 | 20,035 | 19,815 |
| Net block | 24,106 | 13,134 | 12,369 | 11,521 | 12,189 |
| Capital work in progress | 3,699 | 2,692 | 2,423 | 1,201 | 726 |
| Investments | 8,363 | 6,842 | 1,596 | 2,375 | 3,877 |
| Inventory | 5,628 | 3,944 | 3,442 | 3,413 | 3,719 |
| Debtors | 5,416 | 4,085 | 5,220 | 4,417 | 3,340 |
| Cash & bank | 1,417 | 2,957 | 1,105 | 573 | 1,107 |
| Book value (₹) | 269.50 | 238.10 | 197.11 | 173.08 | 166.01 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 2,117 | 6,781 | 3,196 | 2,689 | 2,105 |
| From investing | -8,296 | -8,358 | -1,475 | 1,535 | -1,000 |
| From financing | 5,807 | 1,995 | -1,779 | -4,400 | -868 |
| Net change in cash | -373 | 419 | -58 | -177 | 236 |
| Free cash flow | -6,180 | -1,577 | 1,721 | 4,224 | 1,104 |
| Closing cash | 855 | 827 | 413 | 488 | 1,107 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 21.4 | 26.1 | 24.9 | 13.6 | 15.3 |
| ROE % | 19.7 | 21.1 | 20.5 | 11.6 | 15.5 |
| PAT margin % | 9.7 | 10.1 | 10.1 | 5.9 | 7.9 |
| EBIT margin % | 13.7 | 13.6 | 12.9 | 8.0 | 10.0 |
| Debt / equity | 0.43 | 0.13 | 0.04 | 0.07 | 0.25 |
| Current ratio | 1.27 | 1.89 | 2.14 | 1.81 | 1.55 |
| Interest cover | 16.09 | 32.55 | 60.22 | 20.94 | 23.35 |
| Sales growth % | 16.8 | 18.9 | 13.4 | 14.1 | 4.9 |
| Dividend per share (₹) | 1.00 | 11.00 | 3.00 | 6.00 | 2.50 |
| Payout % | 2.0 | 24.5 | 7.8 | 31.0 | 5.7 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Zydus Lifesciences Ltd. (ZYDUSLIFE) last traded at ₹1,129.40 on the NSE, down +0.49% on the session. Prices on this page are indicative and for information only.
Zydus Lifesciences Ltd. has traded between ₹835.50 and ₹1,232.10 over the last 52 weeks on the NSE.
Zydus Lifesciences Ltd. has a market capitalisation of about ₹1,13,618 crore.
Zydus Lifesciences Ltd. trades at a P/E of 22.6, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for ZYDUSLIFE from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Zydus Lifesciences Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in